GSC
TEVA icon

G&S Capital’s Teva Pharmaceuticals TEVA Stock Holding History

G&S Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-7,011
Closed -$62K – 186
2020
Q1 		$62K Hold
7,011
– – 0.11% 81
2019
Q4 		$68K Buy
7,011
+999
+17% +$8.92K 0.04% 125
2019
Q3 		$41K Buy
6,012
+2,000
+50% +$15.3K 0.02% 123
2019
Q2 		$37K Buy
4,012
+2,000
+99% +$24.1K 0.02% 137
2019
Q1 		$32K Hold
2,012
– – 0.02% 133
2018
Q4 		$31K Hold
2,012
– – 0.03% 117
2018
Q3 		$43K Hold
2,012
– – 0.03% 128
2018
Q2 		$49K Hold
2,012
– – 0.04% 115
2018
Q1 		$34K Buy
2,012
+400
+25% +$7.81K 0.03% 133
2017
Q4 		$31K Buy
+1,612
New +$24.2K 0.02% 146

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

G&S Capital's TEVA Position: Q2 2020 in Review

G&S Capital sold out of Teva Pharmaceuticals (TEVA) in Q2 2020, closing a stake of 7,011 shares — an estimated $62K sold.

G&S Capital first reported a position in TEVA in Q4 2017 and held it in 10 quarters. The position peaked at $68K in Q4 2019. 455 funds tracked by Wall St. Rank hold TEVA as of Q2 2020.

  • G&S Capital reported no remaining Teva Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • G&S Capital sold 7,011 Teva Pharmaceuticals shares in Q2 2020, an estimated $62K.
  • G&S Capital first reported a position in Teva Pharmaceuticals in Q4 2017 and held it in 10 quarters.
  • G&S Capital's Teva Pharmaceuticals position peaked at $68K in Q4 2019.
  • 455 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2020.

Based on G&S Capital's 13F filing for Q2 2020, filed 24 Jul 2020.